Biotech company Moderna, based out of Massachusetts, has shipped its first batches of the COVID-19 vaccine for testing to the US National Institute of Allergy and Infectious Diseases.
According to Fox News, the vaccine will be tested on a group of 45 young, healthy human volunteers at the Kaiser Permanente Washington Health Research Institute in Seattle. Volunteers cannot be infected from the shots, and the purpose of the trial is to ensure that no worrisome side effects emerge.
The company originally believed it would start testing in April, but recent discoveries made from Chinese scientists encouraged a faster turn-around time.
“The speed with which we have [produced these candidates] builds very much on the investment in understanding how to develop vaccines for other coronaviruses,” said Richard Hatchett, CEO of a Norwegian-based company developing a COVID-19 vaccine.
Scientists in China shared the virus’s genome sequence, which is called SARS-CoV-2, which has enabled other countries to continue the development of a vaccine. Though “prototype” pathogens had been researched in previous years, the work was shelved after SARS and MERS epidemics were contained.
According to The Guardian, “SARS-CoV-2 shares between 80% and 90% of its genetic material with the virus that caused SARS—hence its name.”
Despite this speed, releasing a vaccine to the public will still take some time. The…
… Read More
Click here to read the rest of the story from our content source/partners – Christian Headlines.